国际代谢预后指数对接受嵌合抗原受体T细胞治疗的淋巴瘤患者的预后价值
本研究纳入39例接受CD19 CART治疗且具备基线18F-FDG PET/CT及CART后30天随访影像的复发/难治B细胞非霍奇金淋巴瘤患者,评估国际代谢预后指数(IMPI)对无进展生存(PFS)和总生存(OS)的预后价值。IMPI按连续值三分位分组后PFS分层呈显著趋势(p=0.030),而IPI未达显著(p=0.133);IMPI与IPI均与CART后OS无显著关联(均p>0.05)。
要点
- 39例接受CD19 CART的患者中,IMPI三分位分组对PFS分层呈显著趋势(p=0.030)。
- IPI四分位分组对PFS分层未达统计学显著(p=0.133)。
- IMPI与IPI均与CART后OS无显著关联(均p>0.05)。
核心结论
- 在CART背景下,IMPI对PFS估计具有预后价值;与IMPI在一线弥漫性大B细胞淋巴瘤(DLBCL)中的表现不同,本研究未观察到基线IMPI与CART后OS存在显著关联。
研究设计与样本
- 连续纳入接受CD19 CART治疗、具备基线18F-FDG PET/CT及CART后30天随访影像的患者,共39例。
- IMPI由年龄、分期和基线代谢肿瘤体积(MTV)构成,并与国际预后指数(IPI)进行比较。
- 两指数均按既往IPI描述的方法分为四分位组;连续IMPI另按三分位分组以更好区分风险组。
- 总缓解率(ORR)、缓解深度(DoR)和PFS依据Lugano标准判定,采用比例Cox回归分析IMPI和IPI与PFS及OS的关联。
主要发现
- IPI为1、2、3、4、5分的患者分别占23%、21%、26%、21%、10%。
- IMPI低危、中危、高危组30天ORR分别为69%、62%、62%,30天DoR分别为-67%、-66%、-54%,PFS分别为187天、97天、87天。
- ORR和DoR与较低IMPI无相关性(r=0.065,p=0.697)。
- 三分位风险分组对PFS分层呈显著趋势(p=0.030),而IPI未达显著(p=0.133)。
- IPI与IMPI均与CART后OS无显著关联(均p>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The recently introduced International Metabolic Prognostic Index (IMPI) was shown to improve prognostication in the first-line treatment of large B-cell lymphoma. Here, we investigate the prognostic value of the IMPI for progression-free (PFS) and overall survival (OS) in the setting of CD19 CART. METHODS: Consecutively treated patients with baseline 18F-FDG PET/CT imaging and follow-up imaging at 30 days after CART were included. IMPI is composed of age, stage, and metabolic tumor volume (MTV) at baseline and was compared with the International Prognostic Index (IPI). Both indices were grouped into quartiles, as previously described for IPI. In addition, the continuous IMPI was subdivided into tertiaries for better separation of risk groups. Overall response rate (ORR), depth of response (DoR), and PFS were determined based on Lugano criteria. Proportional Cox regression analysis studied association of IMPI and IPI with PFS and OS. RESULTS: Thirty-nine patients were included. The IPI was 1 in 23%, 2 in 21%, 3 in 26%, 4 in 21%, and 5 in 10% of the patients. IMPIlow risk, IMPIintermediate risk, and IMPIhigh risk patients had 30-day ORR of 69%, 62%, and 62% and 30-day DoR of - 67%, - 66%, and - 54% with a PFS of 187 days, 97 days, and 87 days, respectively. ORR and DoR showed no correlation with lower IMPI (r = 0.065, p = 0.697). Dividing patients into three risk groups showed a significant trend for PFS stratification (p = 0.030), while IPI did not (p = 0.133). Neither IPI nor IMPI yielded a significant association with OS after CART (both p > 0.05). CONCLUSION: In the context of CART, the IMPI yielded prognostic value regarding PFS estimation. In contrast with IMPI in the first-line DLBCL setting, we did not observe a significant association of IMPI at baseline with OS after CART.
引用
- Winkelmann M, Blumenberg V, Rejeski K, et al. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2022. PMID: 36513818. doi:10.1007/s00259-022-06075-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。